VitaNova Life Sciences Corporation
VNOV
$4.83
-$2.67-35.60%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 130.17% | 46.22% | -4.24% | 258.65% | 1,081.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 130.17% | 46.22% | -4.24% | 258.65% | 1,081.23% |
| Cost of Revenue | 230.50% | 22.01% | -0.57% | 312.33% | -- |
| Gross Profit | 67.09% | 67.39% | -6.01% | 229.18% | 625.29% |
| SG&A Expenses | 235.32% | 73.39% | -14.67% | -36.84% | 298.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 232.45% | 42.88% | -11.44% | 179.22% | 887.13% |
| Operating Income | -57.12% | 58.47% | 28.63% | 365.11% | 1,745.76% |
| Income Before Tax | -56.88% | 63.32% | 28.63% | 364.22% | 1,735.59% |
| Income Tax Expenses | 158.07% | 125.98% | 41.84% | 332.05% | -- |
| Earnings from Continuing Operations | -160.82% | 9.82% | 16.12% | 376.65% | 1,137.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.82% | 9.82% | 16.12% | 376.65% | 1,137.29% |
| EBIT | -57.12% | 58.47% | 28.63% | 365.11% | 1,745.76% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -160.23% | 10.26% | 15.15% | 377.61% | 203.45% |
| Normalized Basic EPS | -56.79% | 60.87% | 29.41% | 362.86% | 350.00% |
| EPS Diluted | -160.23% | 10.26% | 15.15% | 377.61% | 203.45% |
| Normalized Diluted EPS | -56.79% | 60.87% | 29.41% | 362.86% | 350.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 311.44% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 311.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |